Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis

Osvaldo Artigalás1,2*, Tazio Vanni3, Mara Helena Hutz1, Patricia Ashton-Prolla1,4 and Ida Vanessa Schwartz1,4

Abstract

**Background:** Many clinical trials have shown the efficacy of aromatase inhibitors (AIs) in the management of breast cancer (BC). There is growing evidence that CYP19A1 single-nucleotide polymorphisms (SNPs) are associated with clinical response (CR) and adverse effects (AEs) among BC patients treated with AIs. The aim of this study was to analyze the association between CYP19A1 polymorphisms and AI treatment in BC patients.

**Methods:** A systematic review was performed in MEDLINE, EMBASE, and LILACS. A meta-analysis was conducted to compare the association between CYP19A1 variants and treatment response among BC patients.

**Results:** A total of 12 studies were included in the final analysis. There was significant variation among the populations studied and the SNPs and outcomes investigated. A meta-analysis was only possible for the evaluation of SNP rs4646 vs. the wild-type variant with respect to time to progression (TTP) among metastatic BC patients treated with AI. TTP was significantly increased in patients with the rs4646 variant compared with the wild-type gene (hazard ratio (HR) = 0.51 [95 % confidence interval (CI), 0.33–0.78], P = 0.002). Seven studies analyzed the association between AEs with different polymorphisms of CYP19A1. Although there was a statistically significant association with musculoskeletal adverse events (rs934635, rs60271534, rs700518rs, and haplotype M_3_5) and with vasomotor symptoms (rs934635, rs1694189, rs7176005, and haplotype M_5_3) in individual studies, similar associations were not observed in further studies. No statistically significant association between musculoskeletal AEs and SNPs rs4646, rs10046, rs727479, and rs1062033 was found.

**Conclusions:** These findings suggest that the presence of the rs4646 variant may be a predictive factor of the benefit of AI treatment for BC. The effects of CYP19A1 polymorphisms on clinical outcomes were most often detected in individual studies, suggesting that longer-term studies will better clarify these associations. Additional studies are needed to clarify the predictive value of other SNPs and whether CYP19A1 genotyping should be used to guide AI treatment.

**Keywords:** Adverse effects, Aromatase inhibitors, Breast cancer, Clinical outcomes, CYP19A1, Meta-analysis, Pharmacogenetics, Systematic review

* Correspondence: artigalas@gmail.com
1 Postgraduate Program in Genetics and Molecular Biology, Department of Genetics, UFRGS, Av. Bento Gonçalves, 9500 - Prédio 4323M CEP: 91501-970 - Caixa Postal 15053 Porto Alegre, Rio Grande do Sul, Brazil
2 Genetics Unit, Children’s Hospital, Grupo Hospitalar Conceição, GHC, Av. Francisco Teixeir, 596, CEP 91350-200 Porto Alegre, RS, Brazil
Full list of author information is available at the end of the article

© 2015 Artigalás et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Breast cancer (BC) is the most common cancer among women, and it accounts for the majority of cancer-related deaths among women worldwide, representing 23% of all cancer diagnoses and 14% of cancer-related deaths. In developing countries, BC has also replaced cervical cancer as the current leading cause of cancer deaths among women [1, 2].

Several studies have identified the role of estrogen and its metabolites in the development of BC [3, 4]. Initially, tamoxifen (a selective estrogen receptor modulator) was considered to be the optimal treatment for hormone-responsive BC in both premenopausal and postmenopausal women [5]. Recently, aromatase inhibitors (AIs) have emerged as relatively novel therapeutic options for BC patients [6].

AIs are classified as steroidal (type I, exemestane) and nonsteroidal (type II, anastrozole and letrozole) [7]. Currently, three AIs have been approved by the US FDA and the European Medicines Agency (EMA) for use in postmenopausal women with hormone receptor-positive BC at both the adjuvant and metastatic stages [8]. AI treatment improves disease-free survival (DFS), and lowers the rates of local recurrence, metastatic recurrence, and the incidence of contralateral BC compared with tamoxifen when used as an adjuvant therapy in postmenopausal women with estrogen receptor-positive (ER+) BC [9, 10]. AIs produce significantly lower recurrence rates compared with tamoxifen; either as initial monotherapy or after 2 to 3 years of tamoxifen [9, 10].

Aromatase is a cytochrome P450 enzyme complex that is encoded by CYP19 located on chromosome 15q21.2 [11] and that catalyzes a critical reaction in estrogen biosynthesis involving the formation of aromatic C18 estrogens (estrone and estradiol) from C19 androgens (androstenedione and testosterone) [12]. It is expressed especially in the ovaries as well as several extragonadal tissues (subcutaneous fat, brain, liver, bone, vascular endothelial tissues, and the mesenchymal cells of the adipose tissue in the breast) [12]. Ma et al. [13] 'resequenced' all coding exons, all upstream untranslated exons plus their presumed core promoter regions, all exon-intron splice junctions, and a portion of the 3'-untranslated region of CYP19 using 240 DNA samples from patients of four ethnic groups and identified eighty-eight polymorphisms that resulted in 44 haplotypes. Many studies have reported an association between BC risk and the CYP19A1 genotype [14–16].

Recently, following the publication of randomized clinical trials demonstrating the efficacy of AIs in the treatment of BC [17–19], additional studies have reported associations between CYP19A1 polymorphisms and clinical response (CR) and/or adverse effects (AEs) in BC patients treated with AIs [20, 21]. Considering the potential associations of CYP19A1 polymorphisms with BC risk, estrogen levels and variable aromatase activity levels, it is reasonable to propose that CYP19A1 genotype has an impact on AI treatment response and ultimately patient survival [22].

Retrospective cohort and case–control studies have been published assessing the role of CYP19A1 variants; however, most of these studies involved patients with different characteristics and included only small sample sizes. Consequently, their results are subjected to considerable heterogeneity and uncertainty. The present study is the first to systematically review the international literature and to conduct a meta-analysis of current studies to assess the associations of the CYP19A1 genotype with clinical outcomes and AEs in BC patients treated with AIs.

Methods
This meta-analysis was performed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [23].

Search strategy
MEDLINE, EMBASE, LILACS, and Cochrane databases were searched using the following terms: (“aromatase inhibitor” OR “anastrozole” OR “letrozole” OR “exemestane”) AND (“cyp19a1” OR “aromatase gene” OR “aromatase polymorphism” OR “human cytochrome p450 aromatase” OR “cytochrome p450 19a1” OR “cyp19”). The search was performed on March 30, 2015. No language restrictions were applied. All references from review articles and retrieved articles were screened for additional publications on the subject. A second search was conducted in MEDLINE using the terms “aromatase inhibitors” AND “breast cancer” with the following filters: “clinical trial” AND “published in the last 10 years” AND “English”. A third search was performed using the following strategy: (“first and last author of the articles from the previous search”) AND (“cyp19a1” OR “aromatase gene” OR “aromatase polymorphism” OR “human cytochrome p450 aromatase” OR “cytochrome p450 19a1” OR “CYP19”) OR (“pharmacogenomics” OR “pharmacogenetics”). All titles and abstracts were screened by two independent researchers (OA and TV). During the data extraction process, complementary information not available in the selected articles was also searched for in clinical trial registries (http://www.clinicaltrials.gov, http://www.controlledtrials.com, and the Cochrane Register of Controlled Trials); we also contacted the authors of an included article [24] seeking specific details, but our efforts were unsuccessful.

Selection criteria
Studies met the inclusion criteria and were considered eligible if they involved women with BC who were
treated with AIs (letrozole, anastrozole, or exemestane), genotyped for CYP19A1 and if an assessment of clinical outcomes was included. Non-clinical outcomes or pharmacodynamic studies, case reports, reviews and opinions as well studies of AIs other than letrozole, anastrozole, or exemestane were excluded. If multiple article from the same study were identified, the most recent publication was included in the analysis.

Assessments and data extraction
Two investigators (OA and TV) independently reviewed, evaluated and extracted data from each included article. Conflicting evaluations were resolved following a discussion with a third reviewer (IVS). The review was performed according to the Cochrane Collaboration guidelines [25, 26].

Both authors independently extracted information using pre-designed forms. The following information was extracted: study design, characteristics of participants, setting, intervention, treatment duration, clinical outcome, and AEs. When studies included several subgroups that did not fulfill the inclusion criteria, only those subgroups that met the inclusion criteria were included.

Statistical analysis
Summary hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were estimated for time to progression (TTP). Statistical heterogeneity was assessed by performing the χ² test (assessing the P value) and by calculating the I² statistic. If P < 0.10 and I² > 50 %, indicating heterogeneity, a random-effects model was used; otherwise, the fixed-effects model was used [27]. Analyses were performed using the “metan” package in STATA version 13.0 (StataCorp LP, College Station, Texas, USA) [27]. This package uses the Mantel-Haenszel method to calculate the fixed-effects model. A Forest plot was used to illustrate the results of the meta-analysis.

Results
Search results
The literature search identified 145 publications subject to revision (Fig. 1). A total of 127 articles were rejected after the titles and abstracts were screened, since these were animal models, in vitro studies, or involved drugs other than AIs. Non-English studies and reviews or expert opinions were also rejected. Eighteen articles were fully evaluated. Six were excluded because they did not report relevant clinical outcomes (hormonal and gene expression levels) [24, 28, 29] or assessed AIs in non-BC patients (endometrial cancer) [30–32]. Therefore, 12 studies in total were included. Among these, three assessed AIs as neoadjuvant therapies [33–35], four assessed AIs as adjuvant therapies for patients with stages 0–III BC [36–39], and five assessed AIs as adjuvant therapies for patients with advanced BC (ABC) [20, 21, 24, 40, 41] (Table 1).

Characteristics of the included studies
Most studies (n = 10) involved Caucasian patients. Two included African Americans, who represented less than 10 % of the total sample, another two included Asians, who represented less than 20 % of the total sample. Seven studies included only postmenopausal patients [20, 34–39]. One study included both pre- and postmenopausal patients [21], and four studies did not clearly state this information. In three studies, the sample populations consisted only of patients who received letrozole [20, 21, 35], in two studies, patients received anastrozole [24, 34], and in one study, patients received exemestane alone [39]. In the six remaining studies, the sample populations were composed of women who received any of the three AIs (anastrozole, letrozole, or exemestane).

Association analyses between outcome and CYP19 polymorphisms were heterogeneous. Four studies examined TTP [20, 21, 24, 40], and only two examined overall survival (OS) [24, 40]. One study examined DFS [38], one examined time to treatment failure (TTF) [41], and one examined progression-free survival (PFS) [35]. In addition, Park et al. [22] correlated CYP19 polymorphisms with the clinical benefits (CBs) of AIs according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0. The AEs of AI were described in seven studies [20, 21, 24, 36–39].

In Fig. 2, we describe the key single nucleotide polymorphisms (SNPs) analyzed below, describing their genomic location within the CYP19 gene.

TTP and CYP19A1 variants
Four studies reported an association between CYP19A1 polymorphisms and TTP in women with metastatic ABC [20, 21, 24, 40]. The SNP rs4646 was analyzed in two studies [20, 24], which were meta-analyzed. This analysis demonstrated that TTP is significantly increased in patients with the rs4646 T allele (in homo- or heterozygosis) compared with patients with only wild-type alleles (hazard ratio (HR) = 0.51 [95 % CI, 0.33–0.78], P = 0.002; Fig. 3). No statistical heterogeneity was detected in these analyses (χ² = 0.01, P = 0.929; I² = 0.0 %).

Colomer et al. [20] also analyzed the associations of TTP in relation to two other SNPs but this relationship was not observed for the rs10046 variant (288 vs. 500 days; P = 0.3) or for the rs727479 variant (370 vs. 294 days; P = 0.9). Liu et al. [24] reported the absence of an association between rs10046 variants and TTP (14.93 months vs. 16.89 months; P = 0.94). Miron et al. [40] did not identify associations between TTP and SNPs, rs10046 (P = 0.070), and rs727479 (P = 0.052).
However, they observed an association between increased TTP and the presence of the rs700518 G allele ($P = 0.035$).

Park et al. [21] performed a haplotype analysis and reported that M_1_3 is associated with a significantly longer TTP (11.08 months [95% CI, 6.75–15.42] vs. 5.61 months in non-M_1_3 patients [95% CI, 0.00–11.45], $P = 0.040$) in addition to M_2_1 (12.95 months [95% CI, 9.27–16.63] vs. 7.31 months in non-M_2_1 patients [95% CI, 4.63–9.99], $P = 0.038$). When the analysis considered only the individual variants (in a two-way analysis: homozygous vs. heterozygous), no significant difference in median TTP was observed between SNP carriers and wild-type individuals for rs700518 (12.07 months [95% CI, 8.67–15.46] vs. 7.54 months [95% CI, 6.53–8.55], $P = 0.097$), rs4775936 (11.93 months [95% CI, 8.83–15.04] vs. 7.54 months [95% CI, 6.57–8.51], $P = 0.205$) or rs10459592 (11.93 months [95% CI, 8.66–15.21] vs. 7.74 months [95% CI, 6.51–8.97], $P = 0.176$).

**OS and CYP19A1 variants**

The association between rs4646 and OS was described in two studies. Liu et al. [24] reported a statistically significant association between the presence of one or two rs4646 T alleles (G/T or T/T) and increased OS in women with metastatic BC: 37.3 months vs. 31.6 months (HR, 2.37 [95% CI, 1.20–4.65], $P = 0.001$). However, Miron et al. [40] did not detect a significant association with OS after analyzing the same SNP. SNP rs10046 was also studied in these two papers. Miron et al. [40] described a significantly increased OS in patients carrying the T allele ($P = 0.046$). However, Liu et al. [24] failed to observe a similar association with OS ($P >0.050$). In addition, Miron et al. [40] studied two other SNPs, including rs727479, which was also associated with significantly increased OS when heterozygous (T/G) ($P = 0.003$) or homozygous (T/T) ($P = 0.080$). In the same study, rs700518 was not associated with a change in OS ($P >0.050$).
DFS and CYP19A1 variants
Miron et al. [40] performed the only study examining DFS, which included 53 patients and assessed four SNPs. The presence of SNPs rs4646 ($P$ > 0.050), rs10046 ($P$ = 0.630), or rs700518 ($P$ > 0.050) was not associated with DFS. The presence of SNP rs727479 T allele was associated with increased DFS in both heterozygous (G/T) ($P$ = 0.011) and homozygous (T/T) individuals ($P$ = 0.040).

TTF and CYP19A1 variants
Ferradelschi et al. [41] examined TTF in 308 women with metastatic BC treated with AIs, including 56 variants of CYP19A1. Patients carrying the rs4775936 T allele were found to exhibit significantly increased TTF relative to patients with the reference allele (HR, 0.79 [95% CI, 0.66–0.95], $P$ = 0.012). Similar results were observed in patients with more than 7 TTTA repeats in SNP rs60271534 compared with fewer repeats (HR, 0.84 [95% CI, 0.7–0.99], $P$ = 0.04). Notably, when subjected to a multivariate analysis, these SNPs exhibited no significant association with TTF.

PFS and CYP19A1 variants
Garcia-Casado et al. [35] examined PFS in 95 women with postmenopausal BC treated with neoadjuvant letrozole with a median follow-up time of 40.6 months. Patients with the rs4646 A allele [in either heterozygous (A/C) or homozygous (A/A) status] did not present a significant

---

**Table 1 Characteristics and methodological aspects of studies included in the meta-analysis/systematic review**

| Study (year) | Country | Ethnicity | No. of patients | Clinical set | Menopausal status | Aromatase inhibitors | Main SNPs/haplotypes (total analyzed) | Main outcomes | A | E | L | NR |
|-------------|---------|-----------|----------------|-------------|------------------|---------------------|----------------------------------------|---------------|---|---|---|----|
| Fontein et al. [39] | Netherlands | C | 737 | Adj | Post-menopausal | E | rs946353, rs1694189, rs7176005 (30) | AE (MS-AI, VMS) |
| Liu et al. [24] | China | As | 272 | ABC | NR | A | rs10046, rs4646 (2) | OS, TTP, AE |
| Miron et al. [40] | Italy | C | 53 | NR | NR | A, E, L | rs10046, rs4646, rs727479, rs700518 (4) | DFS, OS, TTP |
| Napoli et al. [38] | USA | C (80%), B (19%), As (1%) | 101 | BC Stage 0-III | Post-menopausal | A, E, L | rs4646, rs700518, rs1062033 (3) | AE (MS-AI) |
| Ghimenti et al. [34] | Italy | C | 37 | Neoadj | Post-menopausal | A | rs7176005, rs6493497 (2) | CR (RECIST) |
| Ferraldeschi et al. [41] | UK | C (90%), others (10%) | 308 | ABC | NR | A, E, L | rs4775936, rs60271534, rs10459592, rs11636639, rs8039089 (56) | TTF |
| Park et al. [21] | Korea | As | 109 | ABC | Pre-/post-menopausal | L | rs700518, rs10459592, rs4775936 (46) * Haplotypes: M_1_3, M_2_1, M_3_5, M_5_3 (8) | CR (RECIST), TTP, AE (hot flushes), AM (MS-AI) |
| Mao et al. [37] | USA | C | 390 | Adjuvant BC Stage 0-III | Post-menopausal | A, E, L | rs749292, rs727479, rs10046, rs11575899, rs60271534 (5) | AE (MS-AI) |
| Garcia-Casado et al. [35] | Spain | C | 95 | Neoadj | Post-menopausal | L | rs10046, rs4646, rs700519 (3) | CR (WHO), PFS |
| Wang et al. [33] | USA, UK | C | 45 | Neoadj | NR | A, E, L | rs6493497, rs7176005 (48) | Tumor size |
| Colomer et al. [20] | Spain | C | 67 | ABC | Post-menopausal | L | rs10046, rs4646, rs727479 (3) | TTP, AE, CR (RECIST) |
| Henry et al. [36] | USA | C (88%), B (9%) | 432 | Adj | Post-menopausal | E, L | rs10046, rs1008805, rs10459592, rs1062033, rs11575899, rs2008691, rs2289105, rs2410906, rs28566535, rs28757184, rs3759811, rs4646, rs775938, rs4939497, rs700518, rs7181886, rs727479, rs730154, rs749292, rs752760, rs983938, rs60271534 (24*) | AE (MS-AI), treatment discontinuation |

**Abbreviations:** A, Anastrozole; ABC, Advanced breast cancer; AE, Adverse effect; As, Asian; B, Black; BC Stage 0-III, Breast Cancer stage 0-III; C, Caucasian; CR (RECIST), Clinical response by RECIST criteria; CR (WHO), Clinical response by World Health Organization criteria; DFS, Disease-free survival; E, Exemestane; L, Letrozole; MS-AI, Musculoskeletal symptoms related to aromatase inhibitors; NR, Not reported; OS, Overall survival; PFS, Progression-free survival; SNPs, Single-nucleotide polymorphisms; TTF, Time to treatment failure; TTP, Time to progression; UK, United Kingdom; USA, United States of America; VMS, Vasomotor symptoms

* Main SNPs with statistically significant results discussed and analyzed in this study

* Main outcomes selected for analysis in this study
reduction in PFS (85.7 % vs. 50.9 %; $P = 0.0686$). However, in a subgroup analysis of women who were not subjected to surgery after letrozole induction, this association was significant (100 % vs. 44.1 %; $P = 0.009$).

**CR and CYP19A1 variants**

CRs were assessed by measuring the size of lesions either by direct comparisons of tumor size [32] or using the RECIST score [21, 34].

Wang et al. [33] described the absence of any association ($P > 0.05$) between 48 SNPs (including rs6493497 and rs7176005) and tumor size in pre- and post-AI neoadjuvant treatment in 52 women with BC. Considering responsiveness to treatment as a ≥30 % reduction in tumor volume, Ghimenti et al. [34] did not observe a statistically significant association in relation to SNPs rs6493497 and rs7176005 in a neoadjuvant scenario. Park et al. [21] allocated patients achieving a complete response or a partial response or patients with stable disease for more than 6 months (standard deviation of approximately 6 months) to the CB group. Patients presenting progressive disease or stable disease for <6 months during treatment were placed in the non-CB group. They analyzed 47 SNPs and identified statistically

---

**Fig. 2** Genomic organization of CYP19A1 gene and the location of key SNPs. Nine coding exons are indicated in black boxes and non-coding regions indicated by white boxes. Position number refers to the +1ATG start codon of GeneBank accession number NC_000015.

---

**Fig. 3** Forest plot showing the association of SNP rs4646 with TTP.
significant associations between CB and rs700518 (OR, 2.52 [95 % CI, 1.02–6.20]; \( P = 0.044 \)), rs10459592 (OR, 2.61 [95 % CI, 1.6–6.46]; \( P = 0.038 \)) and rs4775936 (OR, 2.89 [95 % CI, 1.16–7.22]; \( P = 0.023 \)) after adjusting for age, HER2 positivity, number of metastatic lesions, and liver metastasis. Haplotype analysis revealed an association between CB and haplotypes \( M_1 \_3 \) (OR = 5.33 [95 % CI, 1.63–17.45]; \( P = 0.006 \)) and \( M_2 \_1 \) (OR, 3.37 [95 % CI, 1.43–7.90]; \( P = 0.005 \)).

**AEs and CYP19A1 variants**

Compared with tamoxifen, AIs are associated with higher risks of osteoporosis, fractures, cardiovascular complications, and hypercholesterolemia. In addition, AIs are associated with musculoskeletal side effects and may block ovarian function causing, for example, hot flushes [42]. AEs were reported in seven of the 11 articles included in this review. Nonetheless, one of the seven articles only reported the presence or absence of any AE [20], and they did not observe significantly increased frequencies of any AEs when analyzing SNPs rs4646, rs10046, or rs727479 in 67 women with postmenopausal ABC treated with letrozole. No patient in this study interrupted treatment due to AEs.

**Vasomotor symptoms (VMS)**

Fontein et al. [39] observed 737 patients receiving adjuvant exemestane and noted that the homozygous AA genotype of rs934635 was associated with a significantly higher odds of VMS (univariate analysis OR, 2.86 [95 % CI, 1.12–7.27]; \( P = 0.044 \)), and multivariate analysis OR, 2.78 [95 % CI, 1.02–7.56]; \( P = 0.044 \)). In addition, for rs7176005, the homozygous variant genotypes (TT) were associated with a higher odds of VMS (univariate OR, 4.9 [95 % CI, 1.02–23.5]; \( P = 0.06 \)). Finally, the rs16964189 SNP was associated with the occurrence of VMSs for the homozygous TT genotype (univariate OR, 1.76 [95 % CI, 0.79–3.92]; \( P = 0.025 \)) and multivariate OR, 1.86 [95 % CI, 0.76–4.59]; \( P = 0.06 \)). Park et al. [21] described an association between haplotype \( M_5 \_3 \) (including rs1902586, rs7181886, rs936306, rs1902582, rs16964254, and rs28566535) and hot flushes (OR, 4.12, [95 % CI, 1.09–15.61]; \( P = 0.03 \)).

**Musculoskeletal adverse events (MS-AEs)**

In relation to treatment-related MS-AEs, Liu et al. [24] found that the proportion of AEs among women with metastatic BC treated with anastrozole did not differ when stratified by SNPs rs4646 (\( P = 0.894 \)), rs10046, rs2830, rs9926298, and rs9939609 (data not shown). Fontein et al. [39] reported that the homozygous AA genotype of rs934635 was associated with a significantly higher odds of MS-AEs compared to wild-type GG and GA, with an OR, 4.62 [95 % CI, 1.79–12.0]; \( P = 0.007 \) in the univariate analysis. Multivariate analyses were adjusted for age, BMI, and adjuvant chemotherapy and revealed an OR, 5.08 [95 % CI, 1.8–14.3]; \( P = 0.007 \). However, this association was not found in any other of the 29 SNPs analyzed. Furthermore, Henry et al. [36] analyzed 138 variants in 24 genes (including 23 CYP19A1 SNPs) in 432 BC patients and observed a non-significant increase in MS-AEs when at least eight rs60271534 repeat alleles were present (HR, 1.8 [95 % CI, 0.8–1.8], \( P = 0.49 \)). No other associations were identified.

Park et al. [21] described the association between haplotype \( M_3 \_5 \) (including rs12148604, rs4646, rs10046, rs700519, rs4324076, rs700518, rs3759811, rs727479, rs4775936, rs10459592, rs767199, rs10519297, rs1062033, rs2008691, rs1008805, and rs17523527) and MS-AEs (bone pain and arthralgia) in 66 of 109 patients included in their study (OR, 11.25 [95 % CI, 1.17–108.28]; \( P = 0.01 \)), but no other significant associations were reported. Finally, Mao et al. [37] analyzed five SNPs in 390 patients, reporting no association between MS-AEs and SNPs rs749292 (\( P = 0.57 \)), rs727479 (\( P = 0.94 \)), rs10046 (\( P = 0.20 \)), or rs11575899 (\( P = 0.80 \)). For SNP rs60271534, subjects with at least one TTTA 7-repeat allele had a non-significant 1.7-fold increase in odds of AIAA (OR, 1.70 [95 % CI, 1.06–2.73]; \( P = 0.028 \)) after correcting for multiple testing, whereas patients with at least one TTTA 8-repeat allele had a lower risk of aromatase inhibitor-associated arthralgia (AIAA) (OR, 0.41 [95 % CI, 0.21–0.79]; \( P = 0.008 \)). In addition, Napoli et al. [38] analyzed 97 patients treated with AIs and assessed the possible associations between SNPs rs4646, rs700518, and rs1062033 and bone loss. They did not observe any significant phenotypic differences in patients with distinct genotypes with respect to rs4646 and rs1062033. The presence of the homozygous rs700518 A allele (AA) was associated with a greater loss of bone mineral density in both the lumbar spine (\( P = 0.03 \)) and hip (\( P = 0.03 \)) compared with other genotypes (AG + GG).

**Discussion**

There is growing evidence that polymorphic gene variants can contribute to differences in complex traits between individuals, and the assessment of genes involved in drug metabolism will provide valuable information for treatment planning. Although AI efficacy among BC patients has been proven, there is significant variability in response rate and AE frequency. Therefore, tests that are able to predict treatment response and prognosis would be valuable in the management of these patients. We investigated evidence of the association between CYP19A1 genotypes and clinical outcomes following treatment with AIs in BC patients. A total of 12 studies were included in this systematic review. To our
knowledge, this is the first systematic review and meta-analysis published on the association between CYP19A1 polymorphisms and AI treatment in BC patients.

TTP was analyzed as an outcome in four studies [20, 21, 24, 40]. In this meta-analysis, SNP rs4646 was the only SNP associated with increased TTP, suggesting that this variant is likely involved in the response to AI throughout tumoral evolution. SNPs rs10046 [20, 24, 40], rs700518 [21, 40], and rs727479 [20, 24] did not exhibit any associations with TTP. Due to the heterogeneity between the patient groups, pooling of data was only possible for SNP rs4646.

Liu et al. [24] reported an association between SNP rs4646 and increased OS (P = 0.007), but the same was not observed for SNP rs10046 (P >0.05). In contrast, Miron et al. [40] found no association between OS and rs4646 (P >0.05) but did identify an association between OS and rs10046 (P = 0.003). These conflicting data suggest that CYP19A1 genotypes may be associated with OS in BC patients treated with AIs. However, the magnitude of this association appears highly variable between patients.

The variations in the definitions of DFS, PFS and TTF among studies limited pooling in our analysis. The results involving DFS (positive association with SNP rs727479, P = 0.011), TTF and PFS (no significance association with any SNP) were quite limited in terms of number and heterogeneity of studies, but the overall lack of effect observed may indicate that there are in fact no differences or that the follow-up times used were insufficient to detect relapse/recurrence.

Six studies reported AEs related to AIs [20, 21, 24, 36–38], but only five studies specifically described these AEs as hot flushes [21] or as musculoskeletal complaints [20, 24, 36–38], and the majority did not analyze their associations with SNPs. Notably, SNPs rs4646, rs10046, rs727479 and rs1062033 were evaluated in three studies. None of them reported significant associations between CYP19A1 SNPs and MS-AEs arising from AI treatment [20, 24, 37, 38].

This systematic review and meta-analysis was subjected to limitations. There was inherent heterogeneity in the patient characteristics, polymorphisms, AIs used, clinical settings, and pretreatment regimens. Most of the studies included were retrospective. Therefore, we cannot exclude that other unknown confounders may have biased the results. Studies describing adherence to AI treatment are important because the limited data available have suggested that the most common reason for discontinuing treatment is MS-AEs, which was reported to be responsible for treatment discontinuation in 10–20% of the patients in all of the included studies [43–45]. It is possible that reduced compliance by some patients may have led to underestimation of the benefits of AI treatment.

Furthermore, it is important to mention that this systematic review/meta-analysis might have some publication bias, because we prioritized the inclusion of English publications. Moreover, it is well known that often studies that find negative results, i.e., with no statistically significant correlation between genetic polymorphisms and clinical outcomes, are more rarely published, which may cause a possible limitation in this kind of study. This meta-analysis did not use single patient data, which although more challenging, may have certain advantages over aggregate-level analyses [46]. Furthermore, many of the works included herein were performed without knowledge of other polymorphisms (in CYP19A1 gene, as well in other genes involved in steroidogenesis) that could influence the outcomes analyzed.

Conclusions
This systematic review of the literature revealed associations between CYP19A1 polymorphisms and clinical outcomes and AEs in BC patients receiving AIs. The effects of CYP19A1 polymorphisms on clinical outcomes were most often detected in individual studies, suggesting that longer-term studies will better clarify these associations. Results, such as the association of SNP rs4646 with longer TTP as well as the association of rs934635 and M_3_5 haplotype with VMS and the genetic variants M_3_5, rs700518 and rs60271534 with osteoarticular symptoms, are significant outcomes indicating the impact of these variants on treatment with AIs in BC. Hence, CYP19A1 polymorphisms are potentially useful biomarkers for predicting prognosis and AE profiles in BC patients and may become a promising tool to aid physicians in making therapeutic decisions in the future, although the exact role of CYP19A1 has yet to be clarified when taking the different clinical settings and disease stagings into account. Additional studies must be conducted with larger sample sizes, more homogeneous patient populations (including clinical, demographic, ethnic and genetic aspects), and using standardized outcomes and genotyping strategies to allow for a comprehensive understanding of these associations.

Abbreviations
ABC: Advanced breast cancer; AIs: Adverse effects; AIs: Aromatase inhibitors; BC: Breast cancer; CB: Clinical benefit; CR: Clinical responses; DFS: Disease-free survival; FDA: US Food and Drug Administration; HRs: Hazard ratios; M-S-AEs: Aromatase inhibitor-related musculoskeletal adverse events; OR: Odds ratio; OS: Overall survival; PFS: Progression-free survival; RECIST: Response Evaluation Criteria In Solid Tumors; SNP: Single nucleotide polymorphism; TFF: Time to overall failure; TTP: Time to progression; VMS: Vasomotor symptoms.

Competing interests
The authors declare that they have no conflicts of interest.

Authors’ contributions
OA conceived of the study and participated in its design, study evaluation for inclusion, data interpretation, and wrote the manuscript. TV participated...
References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
3. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000;27:67–73.
4. Cavalieri E, Freinkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000;27:77–93.
5. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008;19:16–27.
6. Schneider R, Barakat R, Pippen J, Osborne C. Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer (Dove Med Press). 2011;3:113–21.
7. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17). J Steroid Biochem Mol Biol. 2011;125:13–18.
8. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Barnadas A, et al. A randomized trial of letrozole in postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25:486–92.
9. Goss PE, Ingle JN, Martinos S, Robert NJ, Mueh HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.
10. Colomer R, Monzo M, Tusquets I, Refa J, Baena JM, Barnadas A, et al. Single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res. 2008;14:811–6.
11. Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J, et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2011;68:1263–71.
12. Hadfield KD, Newman WG. Pharmacogenetics of aromatase inhibitors. Pharmacogenomics. 2012;13:699–707.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009;6:e100097. doi:10.1371/journal.pmed.100097.
14. Goss PE, Ingle JN, Martino S, Robert NJ, Mueh HB, Piccart MJ, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary with response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2005;65:1105–11.
15. Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, et al. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat. 2005;91:137–43.
16. Talbott KE, Gammnon MD, Klibra MY, Chen Y, Teitelbaum SL, Long CM, et al. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat. 2008;114:481–7.
17. Arimexid, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. Effect of aromatase and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year follow-up of the ATAC trial. Lancet Oncol. 2008;9:545–53. doi:10.1016/S1470-2045(07)70385-6.
18. Coates AS, Keshaviah A, Thúrlimann B, Mouridsen H, Marnadiu C, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with estrogenic-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 2007;25:486–92.
19. Goss PE, Ingle JN, Martinos S, Robert NJ, Mueh HB, Piccart MJ, et al. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat. 2008;114:481–7.
35. García-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, et al. A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer. 2010;10:36.

36. Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, et al. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat. 2013;138:807–16.

37. Mao JJ, Su H, Feng R, Donelson ML, Aplenc R, Rebbeck TR, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res. 2011;13:R8.

38. Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER+ breast cancer. Bone. 2013;55:309–14.

39. Fontein DB, Houtsma D, Nortier JW, Baak-Pablo RF, Kranevanger EM, van der Straaten TR, et al. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial. Breast Cancer Res Treat. 2014;144:599–606.

40. Miron L, Negura L, Peptanariu D, Marinca M. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer. Rev Med Chir Soc Med Nat Iasi. 2012;116:997–1004.

41. Ferraldeschi R, Arnedos M, Hadfield KD, A’Hern R, Drury S, Wardley A, et al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat. 2012;133:1191–8.

42. Amir E, Seruga B, Niraalul S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.

43. Crew KD, Greenlee H, Capodice J, Raptis G, Brainin L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877–83.

44. Presant CA, Bosserman L, Young T, Vakil M, Homs R, Upadhya G, et al. Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007(2):775–8.

45. Henry NL, Giles JT, Steams V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park). 2008;22:1401–8.

46. Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005;5:14.